The deal with WSU is the latest in a string of collaborations initiated by Arrayit to jumpstart the diagnostics subsidiary it founded earlier this year. Arrayit believes such a test could enable clinicians to screen for early-stage ovarian cancer in asymptomatic women.
WSU and the Michigan Technology and Research Institute are seeking funding to form a company to shepherd to clinical trials WSU's first candidate, a triple uptake inhibitor for treating depression. They eventually hope to attract a pharma partner for further development.
Georgia Biotech Tort-Shield Bill, Michigan 'Cluster of Innovation,' Maryland Nanobiotechnology Grants, North Carolina Biotechnology Center, Solano Economic Development Corp., Hong Kong Stimulus Package